- April 19, 2023Be sure to catch up on the latest happenings in our spring newsletter here!
- February 2, 2023Be sure to catch up on the latest happenings in our winter newsletter here!
- November 30, 2022November 5, 2022 CAMBRIDGE, Mass., Nov. 05, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing…
- November 16, 2022Be sure to catch up on the latest happenings in our fall newsletter here!
- November 1, 2022Positive high-level results from the NEURO-TTRansform Phase III trial in patients with hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN) showed eplontersen met…
- November 1, 2022October 2022 Webinar Event View Webinar Here This webinar will cover the cardiac and neurologic manifestations of hereditary amyloidosis, diagnostic…
- September 16, 2022CAMBRIDGE, Mass. and TARRYTOWN, N.Y., Sept. 16, 2022 (GLOBE NEWSWIRE) — Intellia Therapeutics, Inc. (NASDAQ:NTLA) and Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) today announced positive interim results from an ongoing…
- August 24, 2022CAMBRIDGE, Mass.–(BUSINESS WIRE)–Oct. 27, 2021– Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that the HELIOS-A Phase 3…
- July 14, 2022Read our latest newsletter here.
- July 14, 2022July 2022 Webinar Event View the recorded webinar below View Webinar Here Dr. Zonder will describe recent advances in the…
7151 N. Main St. Ste. 2 Clarkston, MI 48346
248-922-9610